Precision Medicine in the CICU: Identifying Proteomic Biomarkers

NCT06642662 | Enrolling By Invitation FDA Device

• 1 other identifier: IRB-P00049754
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Congenital Heart disease (CHD) is a leading cause of childhood death. Substantial morbidity and mortality relates to the postoperative course. For example, only 70% of neonates survive to hospital discharge after their first complex surgery for single ventricle heart disease. Adverse systemic inflammatory responses are highly exaggerated in some children postoperatively. This inflammation is pathological, results in leaky blood vessels and fluid overload, toxin release as well as cell damage contributing to lung, heart and kidney injury. Reasons why some children develop this amplified systemic inflammatory response after heart surgery while others do not are poorly understood. Mechanisms for how cardiopulmonary bypass and surgery drive this inflammation are also inadequately characterized. Currently, there are no existing methods to predict patients at high-risk for acute adverse postoperative complications, let alone adjust our management to mitigate these effects. Instead, our postoperative care approach is a one-size fits all, reactive process 'after' patients become inflamed or adverse events occur. Proteins in a patient's blood participate in and reflect acute inflammatory responses. In other pediatric conditions, protein biomarkers have been shown to both predict and monitor inflammation and adverse outcomes, and importantly predict responsiveness to anti-inflammatory drug therapies. This is the premise of precision medicine. Personalizing treatment to each individual patient. New technologies now allow the levels of tens of thousands of proteins to be measured from a few drops of blood. In this proposal the investigators will identify predictors of adverse events after heart surgery by quantifying protein levels and their changes after surgery. It is now possible to detect those proteins with the greatest variability in the postoperative course over time, and between patients, as well as those that are associated with adverse outcomes. The most informative proteins will yield insights into the causes of the inflammatory response. The investigators anticipate identifying protein plasma biomarkers in pathways associated with inflammation, metabolism, blood vessel function and the immune system as these may be key mechanisms involved. Advanced understanding of these mechanisms is critical to deriving targeted therapies to prevent or mitigate inflammatory responses. The investigators will also collect patient clinical data, such as age, cardiac anatomy, and duration of surgery. By combining this clinical information with blood protein profiles, the investigators will be able to develop a model predicting patients at highest risk for adverse postoperative events using machine learning approaches. The overarching goal of this research integrating clinical and bench research is ultimately to translate precision medicine approaches to the Cardiac ICU. Guiding personalized care of high-risk patients by enabling clinicians to anticipate outcomes and tailor decision-making at the bedside will undoubtably improve outcomes in CHD.

Conditions

Congenital Heart Disease

Keywords

proteomic; pediatric cardiac surgery; cardiopulmonary bypass

Outcome Measures

Primary Outcomes (1)

• Time in hours to successful extubation

  Time to successful extubation in hours

  through ICU admission, average 1 week

Secondary Outcomes (2)

• Extent of fluid overload

  3 days

• Composite adverse outcome

  7 days

Study Arms (3)

DTGA ASO

D-transposition of the great arteries (DTGA) post arterial switch operation (ASO)

Diagnostic Test: Somascan 5.0

S1P

Neonates undergoing stage 1 palliation (S1P) for hypoplastic left heart syndrome (HLHS)

Diagnostic Test: Somascan 5.0

BiV

Prior single ventricle palliation now undergoing biventricular (BiV) repair

Diagnostic Test: Somascan 5.0

Interventions

Somascan 5.0 DIAGNOSTIC_TEST

This observational study will test patient plasma using the SomaScan platform, a highly multiplexed proteomic tool that uses SOMAmers (Slow Off-rate Modified Aptamers) to bind with high specificity and affinity to preselected proteins to quantify levels. SomaScan v5.0 quantifies 10,778 clinically relevant human proteins, with several thousand proteins linked to inflammation and immune system functions, across a wide range of concentrations (\>10 logs) with high sensitivity (\<1 pg/mL) and reproducibility (median coefficient of variation \< 5%). Individual protein concentrations are transformed into a corresponding SOMAmer concentration and quantified using a DNA microarray read-out.

BiV; DTGA ASO; S1P

Eligibility Criteria

• Age: 2 Days - 5 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

Prospective patients undergoing S1P for HLHS, BiV repair, or ASO will be identified. Inclusion: elective BiV repair in patients aged \>1 and \<5 years or standard risk S1P/ASO. Exclusion: preoperative ventilation or vasoactive support. With primary treating team approval, the investigators will approach parents of eligible patients to discuss study participation with written informed consent obtained if they agree to enroll.

You may qualify if:

• consent from parents
• cardiac surgical criteria and age criteria; elective BiV repair in patients aged \>1 and \<5 years or standard risk S1P/ASO

You may not qualify if:

• preoperative ventilation or vasoactive support or ECMO

Sponsors & Collaborators

• Boston Children's Hospital: lead

Study Sites (1)

Boston Children's Hospital

Boston, Massachusetts, 02115, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma

MeSH Terms

Conditions

Heart Defects, Congenital

Condition Hierarchy (Ancestors)

Cardiovascular Abnormalities; Cardiovascular Diseases; Heart Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Weeks
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of Palliative Care Services, Division of Cardiovascular Critical Care, Department of Cardiology

Study Record Dates

• First Submitted: October 9, 2024
• First Posted: October 15, 2024
• Study Start: April 15, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): April 15, 2027
• Last Updated: April 2, 2026

Record last verified: 2026-03

Locations

US (1)